Non-pulmonary comorbidities in idiopathic pulmonary fibrosis

Introduction: Idiopathic pulmonary fibrosis (IPF) is a lethal disease affecting older individuals.Recognition and treatment of non-pulmonary comorbidities may improve the quality of life of these patients.Methods: Data from the European IPF Registry were used. The patients and physicians questionnaire from 386 patients with IPF, 60 with hypersensitivity pneumonitis (HP), 85 with ILD in the frame of a collagenosis, 70 patients with COPD and 85 with lung cancer were analysed.Results: The mean age of IPF patients (71% males) was 66,84± 11,22 years. The mean % predicted of FVC was 65,75 ± 23,59 and of DLCO 40,30 ±17,8.The prevalence of the non-pulmonary comorbidities is shown in the following table. Non-pulmonary comorbidities in IPF and other lung diseasesIPFHPILD in the frame of collagenosisCOPDLung CancerGERD31,17%41,30%28%24,19%25,29%Diabetes mellitus (DM)21,68%20,83%15,07%19,67%13,79%Coronary heart disease (CHD)17,38%17,39%21,54%17,74%15,48%Arterial Hypertension (AH)33,01%40,5%41,10%43,10%53,66%Depression9,55%4,26%7,04%9,38%14,77%Sleep apnea9,60%10,00%3,7%8,2%7,1%Non-pulmonary comorbidities were common in patients with IPF. There were no significant differences between IPF and other lung diseases.In a multivariate analysis of patients with IPF including lung function parameters, age and medical treatment with corticosteroids or pirfenidone, AH, CHD and DM were positively correlated to age and negatively correlated to Forced Vital Capacity (p<0,05).Im...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: 1.5 Diffuse Parenchymal Lung Disease Source Type: research